Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 10441128 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Kim Y, et al. (1999) Phosphorylation and activation of phospholipase D1 by protein kinase C in vivo: determination of multiple phosphorylation sites. Biochemistry 38, 10344-51 10441128
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S2-p - PLD1 iso2 (rat) ▲
Orthologous residues
PLD1 (human): S2‑p, PLD1 iso2 (human): S2‑p, PLD1 (mouse): S2‑p, PLD1 iso2 (mouse): S2‑p, PLD1 (rat): S2‑p, PLD1 iso2 (rat): S2‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  3Y1 (fibroblast), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE PKCA (rat)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCA (rat) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, pharmacological activator of upstream enzyme, inhibition of upstream enzyme
 Comments:  co-IP in previous paper
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
GF109203X phorbol ester inhibit treatment-induced increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

T147-p - PLD1 iso2 (rat) ▲
Orthologous residues
PLD1 (human): T147‑p, PLD1 iso2 (human): T147‑p, PLD1 (mouse): T147‑p, PLD1 iso2 (mouse): T147‑p, PLD1 (rat): T147‑p, PLD1 iso2 (rat): T147‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  3Y1 (fibroblast), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE PKCA (rat)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCA (rat) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, pharmacological activator of upstream enzyme, inhibition of upstream enzyme
 Comments:  co-IP in previous paper
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
GF109203X phorbol ester inhibit treatment-induced increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

S561-p - PLD1 iso2 (rat) ▲
Orthologous residues
PLD1 (human): S561‑p, PLD1 iso2 (human): S561‑p, PLD1 (mouse): S561‑p, PLD1 iso2 (mouse): S561‑p, PLD1 (rat): S561‑p, PLD1 iso2 (rat): S561‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  3Y1 (fibroblast), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE PKCA (rat)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCA (rat) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, pharmacological activator of upstream enzyme, inhibition of upstream enzyme
 Comments:  co-IP in previous paper
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
GF109203X phorbol ester inhibit treatment-induced increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.